← Back

Wire · operational-macro

Capricor parts ways with 10% of staff as FDA decision on DMD cell therapy nears

Published

12 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 12 November 2026 · Fusion42 review

Capricor Therapeutics cut 10% of its workforce to focus on its Duchenne muscular dystrophy cell therapy deramiocel, awaiting a key FDA decision following mixed trial results and a regulatory saga. The company has also slowed non-related programs and initiated regulatory engagement in Europe and Japan, while considering expansion into younger patients.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 12 Nov 2026 and 21 Nov 2026.

◆ ◆ The Wire takeaway

You need to prepare for tighter focus and funding constraints as regulatory clearance hangs in the balance and the company cuts unrelated projects. This FDA decision narrows your commercial runway and demands urgent pivot planning.

◆ Coverage

2 sources · first reported 12 Nov 2026 · latest 21 Nov 2026

◆ Related on Wire

◆ Topics

Biotechbiotechfda-decisionlayoffsduchenne-muscular-dystrophyclinical-trials